CLD

Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases

Retrieved on: 
Thursday, March 28, 2024
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Research, CLD, Refractive surgery, ASCRS, Patient, Telecanthus, ARVO, University, Cataract, Abstract, Eyelid, Detail, Society, University of California, Irritation, Safety, MGD, Pain, Ophthalmic, Pharmaceutical industry

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).

Key Points: 
  • Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD).
  • This includes new, long-term data at ASCRS of the company’s lead drug candidate, AZR-MD-001, showing improvement in both signs and symptoms in MGD and Contact Lens Discomfort (CLD).
  • “Together, the data set we are presenting at these prestigious conferences show multiple potential patient benefits and mild, transient side effects in a topical medicine, supporting the potential of AZR-MD-001 as an entirely new approach targeting the underlying cause of many ocular surface diseases,” said Marc Gleeson, Chief Executive Officer of Azura.
  • This causes inflammatory ocular surface conditions, ocular surface dryness, pain, irritation, and reduced quality of vision.

Space Executive Clay Mowry Joins Vast as Advisor

Retrieved on: 
Thursday, March 28, 2024
Technology, Aerospace, Manufacturing, Satellite, Astronaut, International Astronautical Federation, CLD, Growth, Blue Origin, Voyager, Blue, IAF, Commercial, NASA, Multimedia

Vast, a pioneer in space habitation technologies, announces the appointment of Clay Mowry as its newest Advisor.

Key Points: 
  • Vast, a pioneer in space habitation technologies, announces the appointment of Clay Mowry as its newest Advisor.
  • In his role as Advisor, Mowry will provide guidance and counsel on the growth of Vast’s commercial space station business.
  • "We are delighted to welcome Clay Mowry to Vast as an Advisor," said Max Haot, CEO of Vast.
  • "I am excited to join Vast as an Advisor and contribute to the company's mission of advancing commercial space stations," said Clay Mowry.

AI and Robotics in Cell Line Development: Enhancing Efficiency and Accuracy, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, March 14, 2024
AI, Automation, CLD, Robotics, Research, Artificial intelligence, CMX, Computer data storage

TORONTO, March 14, 2024 /PRNewswire-PRWeb/ -- In the specialized field of cell line development (CLD), researchers are constantly grappling with the challenges of maintaining high-throughput efficiency and ensuring clonality, often constrained by manual processes and the intricacies of analyzing sophisticated cell lines. This webinar introduces Cell Metric X (CMX), a portfolio of solutions that builds on a legacy of innovation that integrates artificial intelligence (AI) and robotics into CLD workflows.

Key Points: 
  • In this free webinar, explore how artificial intelligence (AI) and robotics are being used in cell line development (CLD).
  • This webinar introduces Cell Metric X (CMX), a portfolio of solutions that builds on a legacy of innovation that integrates AI and robotics into CLD workflows.
  • Attendees will discover the Cell Metric X portfolio's range, offering versatile levels of automation for every CLD need.
  • Register for this webinar today to explore how AI and robotics are being used in CLD with Cell Metric X.

Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy

Retrieved on: 
Tuesday, March 12, 2024
GPCR, CLD, CDMO, Organization, Partnership, Patient, CGMP, Research, Cutaneous T-cell lymphoma, Cancer, G protein-coupled receptor, CTCL, Gq alpha subunit, Therapy, CCR8, Vaccine

Under the terms of the agreement, Chime Biologics will ensure stable cell line development (CLD) and DT-7012 candidate manufacturing to support clinical trials in strategic countries.

Key Points: 
  • Under the terms of the agreement, Chime Biologics will ensure stable cell line development (CLD) and DT-7012 candidate manufacturing to support clinical trials in strategic countries.
  • Chime Biologics' first global modular facility with single-use bioprocessing technology meets international cGMP standards with proven audit track records.
  • Stephan Schann, Chief Scientific Officer of Domain Therapeutics, said: "We're thrilled to collaborate with Chime Biologics, a great scientific and manufacturing expert, to advance DT-7012, our leading anti-CCR8 candidate, to the next development stage.
  • At Domain, we prioritize precision research and innovation and embrace new partnerships with organizations that share our vision and passion to advance immuno-oncology".

International Experts Gather at CLAP@JC Conference in Hong Kong to Discuss Career & Life Development for Youth in 21st Century Digital Era

Retrieved on: 
Wednesday, March 13, 2024
Convention center, Education Bureau, Advisory Committee, Workplace, Education, Club, HKSAR, CLAP, CLD, Parent, Economy, Conference, Talent, Organization, School, Charitable organization, Special, Trust, Non-governmental organization, Policy, Employment, News, Knowledge, Finance, Social, Community, Chairperson, Education University, Hong Kong Jockey Club, OECD, Student, Tutoring

He highlighted that society has now begun to embrace a diversity of choices when it comes to defining a fulfilling and fulfilled life.

Key Points: 
  • He highlighted that society has now begun to embrace a diversity of choices when it comes to defining a fulfilling and fulfilled life.
  • he shared results from the latest Programme for International Student Assessment (PISA), highlighting findings related to the well-being and career development of Hong Kong students.
  • A systematised CLD framework, "Hong Kong Benchmarks for Career & Life Development" (HKBM) has been developed and benchmarked against global best-practice and is now being implemented in one-third of Hong Kong secondary schools and over 115 non-profit youth centres.
  • Thus far, CLAP@JC has engaged 122 local secondary schools, 115 nonprofit youth-service units, and 3,700 employers in its network.

CYTENA Launches The 2nd Generation UP.SIGHT And C.STUDIO - An All-in-one Solution for Industrial Cell Line Development Revolutionizing the Manufacturing of Biologics

Retrieved on: 
Thursday, February 15, 2024
Immortalised cell line, 3D, GMP, Software, CLD, Data analysis, Fine chemical

FREIBURG, Germany, Feb. 15, 2024 /PRNewswire-PRWeb/ -- CYTENA GmbH, a BICO company and a global leader in single cell dispensing technologies, is pleased to announce the launch of the 2nd generation UP.SIGHT - a transformative single-cell dispenser and imager ushering in a new era in stable cell line development workflows.

Key Points: 
  • CYTENA GmbH, a subsidiary of BICO and a leading figure in single cell dispensing technologies, has recently unveiled the 2nd generation UP.SIGHT.
  • The system also introduces the C.STUDIO software, a sophisticated platform for data analysis and reporting tailored to cell line development.
  • CYTENA is also introducing an advanced CLD (Cell Line Development) analysis suite called C.STUDIO, alongside the new generation of UP.SIGHT.
  • It also features comprehensive reporting tools for regulatory submissions, making it the most sophisticated software designed specifically for enhancing cell line development workflows.

MedMen Exits Arizona Market, Completing Sale of Local Operations to MINT Cannabis

Retrieved on: 
Friday, January 5, 2024
Alternative Medicine, Cannabis, Retail, Health, Tobacco, Natural Resources, Specialty, Sale, MedMen, CLD, Cryptocurrency

MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis company with operations across the United States, today announced that the Company has completed the previously announced sale of its non-core business operations in Arizona to an affiliate of Mint Cannabis (“MINT Cannabis”).

Key Points: 
  • MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis company with operations across the United States, today announced that the Company has completed the previously announced sale of its non-core business operations in Arizona to an affiliate of Mint Cannabis (“MINT Cannabis”).
  • The pending sale of the Company’s assets in Nevada to MINT Cannabis awaits regulatory approval for completion.
  • “We are pleased to announce the closing of the sale of our business operations in Arizona.
  • ATB Capital Markets acted as financial advisor and Raines Feldman Littrell LLP acted as legal advisor to MedMen.

MedMen Enters into Definitive Agreements to Exit Arizona and Nevada per Announced Strategic Review, Selling Non-Core Assets to MINT Cannabis

Retrieved on: 
Wednesday, December 20, 2023
Alternative Medicine, Cannabis, Retail, Health, Specialty, Natural Resources, Sale, Acquisition, MINT, MedMen, CLD

MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis company with operations across the United States, today announced that it has entered into definitive agreements to sell its non-core business operations in Arizona and certain assets in Nevada to an affiliate of Mint Cannabis (“MINT Cannabis”), a private multi-state cannabis operator headquartered in Arizona.

Key Points: 
  • MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQX: MMNFF), a premier cannabis company with operations across the United States, today announced that it has entered into definitive agreements to sell its non-core business operations in Arizona and certain assets in Nevada to an affiliate of Mint Cannabis (“MINT Cannabis”), a private multi-state cannabis operator headquartered in Arizona.
  • The transactions consist of the sale of MedMen’s wholly-owned operating subsidiary in Arizona and its two operating dispensaries located in Clark County, Nevada.
  • These sales are the result of MedMen’s previously announced strategic review and evaluation of divestiture opportunities of its non-core assets.
  • “MedMen is pleased with the outcome of our strategic review and has made good progress in our restructuring efforts.

Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Contact lens, CLD, Meibomian gland dysfunction, Safety, Gland, Lens, Eyelid, Irritation, AZR, Dry, Patient, FDA, Ophthalmic, Fluorescein, Contact, MGD, MGS, Pain, Quality of life, Telescopic sight, Azura

This is the second positive Phase 2 study of AZR-MD-001 to demonstrate statistically significant improvements across multiple sign and symptom endpoints in patients with MGD.

Key Points: 
  • This is the second positive Phase 2 study of AZR-MD-001 to demonstrate statistically significant improvements across multiple sign and symptom endpoints in patients with MGD.
  • “MGD is the root cause of many downstream ocular surface conditions that impact quality of life and vision for patients, including Contact Lens Discomfort.
  • This leads to several downstream ocular surface symptoms including dryness, pain, irritation, reduced quality of vision, and Contact Lens Discomfort.
  • “MGD is one of the causes of Contact Lens Discomfort, and many patients give up on wearing contact lenses altogether due to the irritation they experience.

Cell Line Development Market Research Report 2023-2030 Featuring Key Players - Thermo Fisher Scientific, Corning, Lonza, Creative BioLabs., WuXi PharmaTech, Sartorius, Merck, Berkeley Lights, Danaher - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 7, 2023
Health, Pharmaceutical, CLD, Research, Immortalised cell line, GMP, Thermo Fisher Scientific, Fujifilm, Type, Coronavirus, Application, Fujifilm Diosynth Biotechnologies, ATCC (company), Novartis, Sigma-Aldrich, Human, Growth, ATCC, Fine chemical, Pharmaceutical industry, Mobile phone, Vaccine, Nusinersen

Rising use of new healthcare technology and rising cancer incidences, create more attractive and lucrative growth prospects for the CLD market.

Key Points: 
  • Rising use of new healthcare technology and rising cancer incidences, create more attractive and lucrative growth prospects for the CLD market.
  • The expansion and growth of the biologics sector will also be a major CLD market development determinant.
  • For example, CYTENA, a BICO subsidiary, introduced a new platform for entirely automated stable cell line development in October 2021.
  • However, the high capital expenses and expenditure needed to construct research and development capabilities would be a barrier to the cell line development industry.